Frequency Therapeutics Inc Stock

$14.90

1.02% today

Nasdaq, Apr 04, 09:16 pm CET

ISIN

US35803L1089

Symbol

KRRO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Frequency Therapeutics Inc Stock price

$14.75

-746.25 98.06% 5Y

Nasdaq, Closing price Thu, Apr 03 2025

-2.59 14.94%

ISIN

US35803L1089

Symbol

KRRO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Key metrics

Market capitalization	$138.49m
Enterprise Value	$57.16m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	25.18
P/S ratio (TTM) P/S ratio	61.01
P/B ratio (TTM) P/B ratio	0.86
Revenue (TTM) Revenue	$2.27m
EBIT (operating result TTM) EBIT	$-91.91m
Free Cash Flow (TTM) Free Cash Flow	$-77.98m
Cash position	$126.10m
EPS (TTM) EPS	$-9.39
P/E forward	negative
P/S forward	415.47
EV/Sales forward	171.48
Short interest	11.58%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Frequency Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Frequency Therapeutics Inc forecast:

8x Buy

100%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Frequency Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Frequency Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	2.27 2.27	- 100%
- Direct Costs	3.57 3.57	35% 35% 157%
Gross Profit	-1.29 -1.29	77% 77% -57%
- Selling and Administrative Expenses	27 27	56% 56% 1,189%
- Research and Development Expense	60 60	16% 16% 2,646%
EBITDA	-88 -88	18% 18% -3,892%
- Depreciation and Amortization	3.57 3.57	35% 35% 157%
EBIT (Operating Income) EBIT	-92 -92	15% 15% -4,049%
Net Profit	-84 -84	3% 3% -3,682%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Frequency Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

3 days ago

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of Oliver Dolan to Principal Accounting Officer Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & ...

Neutral

GlobeNewsWire

●

17 days ago

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported full-year 2024 financial results, and provided an update on recent progress and anticipated milestones.

Neutral

GlobeNewsWire

●

21 days ago

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational medicine KRRO-11...

More Frequency Therapeutics Inc News

Company Profile

Frequency Therapeutics, Inc. engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Its product pipeline include Sensorineural hearing loss (FX-322), and Multiple Sclerosis. The company was founded by Robert S. Langer, Jr., David L. Lucchino, Christopher Loose and Will J. McLean on November 13, 2014 and is headquartered in Woburn, MA.

Head office	United States
CEO	Ram Aiyar
Employees	104
Founded	2018
Website	www.korrobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now